InterAx achieves milestone that triggers second part of seed investment ahead of schedule
December 2017, Switzerland-Boston: InterAx announced today a successful milestone achievement to trigger the second part of the seed investment led by a team of Boston-based Biotech investors. Martin Ostermaier, CEO of InterAx said: “Our investors were impressed by the speed and quality of how the set goals for 2017 have been achieved, in particular with our success in identifying first hits in our in-house drug discovery program.”
